BCM
GLUE icon

Bridgeway Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Bridgeway Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
552,566
+23,868
+5% +$451K 0.24% 123
2026
Q1 		$8.7M Buy
528,698
+5,321
+1% +$102K 0.17% 175
2025
Q4 		$8.21M Buy
523,377
+164,527
+46% +$2.22M 0.17% 175
2025
Q3 		$2.66M Buy
358,850
+87,450
+32% +$463K 0.06% 455
2025
Q2 		$1.22M Buy
+271,400
New +$1.21M 0.03% 631
2024
Q4 		– Sell
-25,000
Closed -$133K – 1241
2024
Q3 		$133K Buy
+25,000
New +$126K ﹤0.01% 1123

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bridgeway Capital Management's GLUE Position: Q2 2026 in Review

Bridgeway Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 4.5% in Q2 2026, buying an estimated $451K and bringing the position to 552,566 shares worth $13.4M. The position accounts for 0.24% of the portfolio, ranked #123.

Bridgeway Capital Management first reported a position in GLUE in Q3 2024 and has held it in 6 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Bridgeway Capital Management held 552,566 shares of Monte Rosa Therapeutics worth $13.4M as of Q2 2026.
  • Bridgeway Capital Management bought 23,868 Monte Rosa Therapeutics shares in Q2 2026, an estimated $451K.
  • Monte Rosa Therapeutics made up 0.24% of Bridgeway Capital Management's portfolio in Q2 2026, its #123 holding.
  • Bridgeway Capital Management first reported a position in Monte Rosa Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.